High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule.
High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule.
复制标题
DOI：
10.1038/bjc.1997.465
复制
发表时间：
1997
影响因子：
8.8
通讯作者：
Patrone F
中科院分区：
文献类型：
--
作者：
Ballestrero A;Ferrando F;Garuti A;Basta P;Gonella R;Esposito M;Vannozzi MO;Sorice G;Friedman D;Puglisi M;Brema F;Mela GS;Sessarego M;Patrone F
在高剂量范围内米托蒽醌（NOV）的最佳使用需要阐明其最大耐受剂量与外周血祖细胞（PBPC）的支持和药物给药和PBPC回输之间所需的时间间隔，以避免移植物毒性。本研究的目的是：（1）验证在PBPC支持下将NOV递增至90 mg m（-2）的可行性和血液学毒性;（2）验证NOV给药和PBPC回输之间短（96 h）间隔的安全性。三组10名乳腺癌（BC）或非霍奇金淋巴瘤（NHL）患者接受递增剂量的NOV（60、75和90 mg m（-2））加美法仑（L-PAM）（140-180 mg m（-2）），并在NOV后96 h进行PBPC抢救。还评价了NOV血浆药代动力学以及NOV对PBPC的细胞毒性。在各NOV剂量水平下，血液学恢复迅速且完全，无统计学显著性差异，且无重大毒性。PBPC再输注时的NOV血浆浓度低于对造血祖细胞的毒性阈值。结论是，当PBPC充分支持时，NOV可升高至90 mg m（-2），血液学毒性可接受。PBPC可以在NOV给药后96小时安全地再输注。
The optimal use of mitoxantrone (NOV) in the high-dose range requires elucidation of its maximum tolerated dose with peripheral blood progenitor cell (PBPC) support and the time interval needed between drug administration and PBPC reinfusion in order to avoid graft toxicity. The aims of this study were: (1) to verify the feasibility and haematological toxicity of escalating NOV up to 90 mg m(-2) with PBPC support; and (2) to verify the safeness of a short (96 h) interval between NOV administration and PBPC reinfusion. Three cohorts of ten patients with breast cancer (BC) or non-Hodgkin's lymphoma (NHL) received escalating doses of NOV, 60, 75 and 90 mg m(-2) plus melphalan (L-PAM), 140-180 mg m(-2), with PBPC rescue 96 h after NOV. Haematological toxicity was evaluated daily (WHO criteria). NOV plasma pharmacokinetics was also evaluated, as well as NOV cytotoxicity against PBPCs. Haematological recovery was rapid and complete at each NOV dose level without statistically significant differences, and there were no major toxicities. NOV plasma concentrations at the time of PBPC reinfusion were below the toxicity threshold against haemopoietic progenitors. It is concluded that, when adequately supported with PBPCs, NOV can be escalated up to 90 mg m(-2) with acceptable haematological toxicity. PBPCs can be safely reinfused as early as 96 h after NOV administration.
登录
查看更多内容
影响因子：
3
作者：
VANBELLE, SJP;DEPLANQUE, MM;MCVIE, JG
通讯作者：
MCVIE, JG
DOI：
10.1016/0277-5379(89)90382-9
发表时间：
1989-07-01
期刊：
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY
影响因子：
--
作者：
GIANNI, AM;BONADONNA, G
通讯作者：
BONADONNA, G
影响因子：
5.2
作者：
LEMOLI, RM;GULATI, SC
通讯作者：
GULATI, SC
影响因子：
45.3
作者：
VONHOFF, DD;CLARK, GM;LEMAISTRE, CF
通讯作者：
LEMAISTRE, CF
影响因子：
45.3
作者：
WALLERSTEIN, R;SPITZER, G;DEISSEROTH, A
通讯作者：
DEISSEROTH, A